We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Avacta Group plc (AVCT) Ordinary Shares 10p

Sell:70.00p Buy:72.00p 0 Change: 1.00p (1.39%)
FTSE AIM 100:1.15%
Market closed |  Prices as at close on 13 March 2026 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:70.00p
Buy:72.00p
Change: 1.00p (1.39%)
Deal now Deal for just £6.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 13 March 2026 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:70.00p
Buy:72.00p
Change: 1.00p (1.39%)
Market closed |  Prices as at close on 13 March 2026 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £6.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • Avacta upbeat on preCISION comparative study

    24 February 2026 12:56

    (Sharecast News) - Avacta Therapeutics said on Tuesday that new preclinical analysis indicated its proprietary 'preCISION' tumour-activated delivery platform could offer pharmacokinetic advantages...

  • Avacta finds new science chief internally

    9 February 2026 12:00

    (Sharecast News) - Avacta Therapeutics announced the appointment of Francis Wilson as its chief scientific officer on Monday, effective immediately, as the AIM-traded clinical-stage biopharmaceutical company...

  • Avacta agrees two key clinical trial updates

    3 February 2026 13:23

    (Sharecast News) - Avacta Therapeutics said on Tuesday that it had agreed two key clinical protocol updates to its faridoxorubicin, or AVA6000, programme, removing the historic cardiac dosing limit and...

  • Avacta to start trialling second drug after FDA clearance

    21 January 2026 12:33

    (Sharecast News) - Avacta Therapeutics said on Wednesday that it has received clearance from the US Food and Drug Administration for the investigational new drug application for 'FAP-Exatecan', or...

  • Avacta reports strong operational progress

    20 January 2026 13:52

    (Sharecast News) - Avacta Group reported strong operational progress during 2025 on Tuesday as the clinical-stage biopharmaceutical company advanced its preCISION tumour-activated oncology platform,...

  • Avacta upbeat on fresh data from second oncology asset

    18 December 2025 08:55

    (Sharecast News) - Avacta reported new pharmacology data on its second oncology asset, FAP-Exd (AVA6103), on Thursday, showing sustained tumor exposure and prolonged responses across multiple preclinical...

  • Avacta reports 'clinically meaningful' tumour shrinkage in AVA6000 trial

    17 December 2025 17:11

    (Sharecast News) - Avacta Therapeutics said on Wednesday that new data from the phase 1b cohort of its ongoing trial of faridoxorubicin, also known as AVA6000, showed clinically meaningful tumour shrinkage...

  • Avacta presents promising findings to Boston conference

    27 October 2025 09:07

    (Sharecast News) - Shares in Avacta rose on Monday after the clinical stage biopharmaceutical company presented preclinical data showing its novel dual payload pre|CISION technology at a oncology conference...

  • Avacta raises £16m, releases solid clinical trial data

    20 October 2025 09:01

    (Sharecast News) - Avacta Group announced on Monday that it has raised £16m through an oversubscribed equity placing to accelerate development of its oncology pipeline, as new clinical data presented at the...

  • Avacta reports continued progress in second quarter

    2 July 2025 11:03

    (Sharecast News) - Avacta Therapeutics provided a second-quarter business update on Wednesday, reporting continued progress in its oncology pipeline and strengthening of its leadership team as it advanced...

  • Avacta posts narrower full-year losses from continuing operations

    6 June 2025 12:25

    (Sharecast News) - Avacta Group reported a reduced pre-tax loss of £28.98m from continuing operations in 2024 on Friday, down from £31.13m the year prior, as it accelerated its transformation into a...

  • Avacta pushes back annual results due to auditor delays

    27 May 2025 08:58

    (Sharecast News) - Life sciences company Avacta Therapeutics has announced that it has had to delay the release of its annual results by a week.

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2026. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.